SCHEMBL479570

SCHEMBL479570

COC(=O)c1ccc2c(c1)NC(=O)C2=C(Nc1ccc(C(=O)OC(C)(C)C)cc1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
PTPN1 P18031 1/20 0.41
STAT3 P40763 1/20 0.41
MEN1 O00255 5/20 0.40
L3MBTL1 Q9Y468 4/20 0.40
POLB P06746 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
BACE1 P56817 2/20 0.40
CASP1 P29466 1/20 0.40
TP53 P04637 1/20 0.39
THRB P10828 1/20 0.39
BLM P54132 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALDH1A1 P00352 3/20 0.39
GAA P10253 2/20 0.39
MAPT P10636 2/20 0.39
RAB9A P51151 4/20 0.38
NPC1 O15118 2/20 0.38
RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL479568 1.00 KMT2A (0.43) KMT2ACTDSP1PTPN1STAT3MEN1
SCHEMBL3156489 0.91 RXFP1 (0.49) KMT2AMEN1SMN1; SMN2TP53THRB
SCHEMBL479876 0.90 RAB9A (0.46) KMT2ACTDSP1PTPN1MEN1L3MBTL1
SCHEMBL2120036 0.90 RAB9A (0.46) KMT2ACTDSP1PTPN1MEN1L3MBTL1
SCHEMBL2566047 0.89 RAB9A (0.41) KMT2ACTDSP1PTPN1MEN1L3MBTL1
SCHEMBL480665 0.89 KMT2A (0.44) KMT2ACTDSP1PTPN1MEN1L3MBTL1
SCHEMBL480667 0.89 KMT2A (0.44) KMT2ACTDSP1PTPN1MEN1L3MBTL1
SCHEMBL2568537 0.88 KMT2A (0.43) KMT2ACTDSP1PTPN1MEN1L3MBTL1
SCHEMBL480757 0.88 KMT2A (0.43) KMT2ACTDSP1PTPN1MEN1L3MBTL1
SCHEMBL20807346 0.88 KMT2A (0.46) KMT2ACTDSP1PTPN1MEN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9844572-B2 Promotion of neuronal integration in neural stem cell grafts LIFE & BRAIN GMBH (DE) 2017-12-19 US disclosed
EP-2411034-B1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2017-07-26 EP disclosed
US-20120093832-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2012-04-19 US disclosed
EP-2411034-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS Life & Brain GmbH (DE) 2012-02-01 EP disclosed
WO-2010108665-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120093832-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS DCX, NGF, BDNF KMT2A 3904/4885CTDSP1 4624/4885PTPN1 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.